Ugur Sahin, Chief Executive Officer and 10% owner of BioNTech SE (NASDAQ:BNTX), filed a Form 4 on September 22, 2026, reporting the sale of 79,000 ordinary shares across two transactions on September 21 and September 22, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • First sale: 33,000 ordinary shares disposed of on September 21, 2026, at a price of $97.8097 per share.
  • Second sale: 46,000 ordinary shares disposed of on September 22, 2026, at a price of $100.7182 per share.
  • Direct holdings after transactions: 410,209 ordinary shares held directly following the reported transactions.
  • Indirect holdings: 39,218,111 ordinary shares held indirectly through Medine GmbH, of which Sahin is the sole shareholder.
  • Trading plan: Both sales were effected pursuant to a Rule 10b5-1 trading plan established on June 3, 2026.
  • Trust arrangement: 106,721 of the indirectly held shares are held for the benefit of an individual under a trust arrangement, over which Medine GmbH exercises voting power but not dispositive power.

BioNTech CEO Sahin Reports Two-Day Share Sale Under 10b5-1 Plan

According to the filing, Ugur Sahin, who serves as Chief Executive Officer and is identified as a 10% owner of BioNTech SE, sold a combined 79,000 ordinary shares over two consecutive trading days. On September 21, 2026, the filing discloses, Sahin disposed of 33,000 shares at $97.8097 each, reducing his direct beneficial ownership to 456,209 shares. The following day, September 22, 2026, an additional 46,000 shares were sold at $100.7182 each, bringing his directly held position to 410,209 ordinary shares.

The filing states that both transactions were carried out under a Rule 10b5-1 trading plan that Sahin established on June 3, 2026. The form was signed by Humza Bokhari as Attorney-in-Fact on September 22, 2026.

In addition to his direct holdings, the filing reports that Sahin indirectly beneficially owns 39,218,111 ordinary shares through Medine GmbH. According to the filing's footnote, Sahin is the sole shareholder of Medine GmbH, and 106,721 of those shares are held for the benefit of an individual under a trust arrangement. Under that arrangement, the filing states, Medine GmbH "exercises voting power, but not dispositive power" over those particular shares for as long as they remain in trust.

What Was Disclosed

The Form 4 discloses two open-market sales of BioNTech ordinary shares by CEO Ugur Sahin on September 21 and 22, 2026, totaling 79,000 shares, conducted under a Rule 10b5-1 plan established June 3, 2026, with 410,209 shares held directly and 39,218,111 held indirectly through Medine GmbH after the transactions.